Prana Provides Huntington Disease Trial Update in Conjunction With the Huntington Study Group Annual Conference

Prana Biotechnology ( NASDAQ : PRAN ) ( ASX : PBT ) today reported on its progress in the Reach2HD trial, following a presentation by the Ms Dianne Angus, Prana's Chief Operating Officer, at the Huntington Study Group Annual Conference held in Seattle this past weekend.

The Reach2HD trial is a Phase IIa, 6 month trial in 100 patients with early to mid-stage Huntington disease that are treated with one of two doses of PBT2 or placebo. Enrollment commenced in April 2012 following approval from the FDA to conduct the trial across sites in the USA and Australia. All twenty Reach2HD sites are open and recruiting. Based on current recruitment activity, it is expected that over 80% of patients will be in dosing by the end of this month in line with Prana's recruitment completion target at the end of the year and reporting of results in 2H13.

AcelRx Announces Primary Endpoint Met in Phase 3 Non-Inferiority Study of Sublingual Sufentanil NanoTab® PCA System vs. IV PCA Morphine for Post-Operative Pain

-In this open-label study, the Sufentanil NanoTab PCA System also demonstrated statistical superiority to IV PCA morphine for primary endpoint of Patient Global Assessment of method of pain control
- Nurses and patients rated Sufentanil NanoTab PCA System higher for Overall Satisfaction and Ease of Care compared to IV PCA morphine
- AcelRx to conduct conference call and webcast today, November 15, at 8:00 a.m. EST (5:00 a.m. PST) to discuss top-line results in detail

Synergy Pharmaceuticals Reports Third Quarter 2012 Financial Results

Synergy Advances Clinical Programs

Synergy Pharmaceuticals, Inc. (SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today reported its financial results and business update for the third quarter and nine month ended September 30, 2012. Synergy is developing plecanatide for the treatment of chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C).

Gilead Announces 100 Percent Sustained Virologic Response Rate (SVR4) for an Interferon-Free Regimen of Sofosbuvir (GS-7977), GS-5885 and Ribavirin in Treatment-Naïve Genotype 1 Hepatitis C Infected Patients

- Phase 3 Study with a Fixed-Dose Combination Tablet of Sofosbuvir and GS-5885 Now Underway -

Gilead Sciences (GILD) today announced interim data from the ongoing Phase 2 ELECTRON study examining a 12-week course of therapy with the investigational nucleotide sofosbuvir (formerly referred to as GS-7977), the NS5A inhibitor GS-5885 and ribavirin in patients with genotype 1 chronic hepatitis C virus (HCV) infection. Among treatment-naïve patients receiving this combination, 100 percent (n=25/25) remained HCV RNA undetectable four weeks after completing therapy (SVR4). These data will be presented on Tuesday, November 13^th at the 63rd annual meeting of the American Association for the Study of Liver Diseases (The Liver Meeting 2012) in Boston.